BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today ...

OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS PanelEnables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDsOxford, UK ...

An Iranian knowledge-based company has successfully developed “Midovens,” a domestically produced anti-cancer drug that ...

Detailed price information for Astellas Pharma Inc (ALPMF) from The Globe and Mail including charting and trades.

MADRID and CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

Q3 2025 Earnings Call Transcript November 4, 2025 Kura Oncology, Inc. misses on earnings expectations. Reported EPS is ...

Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual Meeting Preliminary data from the ongoing Phase ...

Q3 2025 Management View CEO Troy Wilson reported significant progress for ziftomenib, Kura's investigational menin inhibitor for acute myeloid leukemia (AML), emphasizing that "the FDA review of ...

The firm is now offering combined ex vivo drug sensitivity and genomic testing to cancer patients outside the clinical trial setting.

Net loss for the third quarter of 2025 was $74.1 million, compared to a net loss of $54.4 million for the third quarter of 2024. Net loss for the third quarter included non-cash share-based ...

Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) ...